SCHEMBL6434567

SCHEMBL6434567

CCOC(=O)c1ncoc1-c1cccc(C(=O)Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FBP1 P09467 1/20 0.49
GSK3B P49841 2/20 0.43
TP53 P04637 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ELANE P08246 2/20 0.40
ADORA2A P29274 1/20 0.40
TARBP2 Q15633 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6437289 0.89 FBP1 (0.53) FBP1GSK3BTP53POLBHPGD
SCHEMBL9587212 0.85 ALOX5 (0.52) FBP1ALDH1A1MAPTELANETARBP2
SCHEMBL6437536 0.85 FBP1 (0.49) FBP1GSK3BTP53POLBHPGD
SCHEMBL6439226 0.83 TP53 (0.46) FBP1GSK3BTP53POLBHPGD
SCHEMBL9586836 0.83 FBP1 (0.51) FBP1GSK3BMEN1KMT2AALDH1A1
SCHEMBL5727790 0.82 FBP1 (0.69) FBP1GSK3BTP53HPGDMEN1
SCHEMBL30740878 0.81 FBP1 (0.49) FBP1GSK3BPOLBHPGDMEN1
SCHEMBL9585814 0.79 ALOX5 (0.51) FBP1GSK3BMAPTTARBP2
SCHEMBL28554485 0.78 FBP1 (0.51) FBP1GSK3BHPGDMEN1KMT2A
SCHEMBL9585840 0.77 GAA (0.60) FBP1POLBHPGDNPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379522-B1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I HOFFMANN LA ROCHE (CH) 2005-01-26 EP disclosed
EP-1379522-A1 DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2004-01-14 EP disclosed
US-6548495-B2 Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders HOFFMANN-LA ROCHE INC. 2003-04-15 US disclosed
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives HOFFMANN-LA ROCHE INC. 2002-12-26 US disclosed
WO-2002083665-A1 DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I F. HOFFMANN-LA ROCHE AG (CH) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198197-A1 Dihydro-benzo [b] [1,4] diazepin-2-one derivatives BDKRB1, BDKRB2, GRIN1 FBP1 1088/4885GSK3B 1356/4885TP53 4824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.